Tumor Immunology and Immunotherapy – Cellular Methods Part A - 1st Edition - ISBN: 9780128186732, 9780128186749

Tumor Immunology and Immunotherapy – Cellular Methods Part A, Volume 631

1st Edition

0.0 star rating Write a review
Serial Volume Editors: Lorenzo Galluzzi Nils-Petter Rudqvist
Hardcover ISBN: 9780128186732
eBook ISBN: 9780128186749
Imprint: Academic Press
Published Date: 17th January 2020
Page Count: 554
Sales tax will be calculated at check-out Price includes VAT/GST
278.14
199.00
169.15
138.00
142.00
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry
Jeremy B. Foote, Sujith Sarvesh and Leisha A. Emens
2. High-throughput identification of human antigen-specific CD8+ and CD4+ T cells using soluble pMHC multimers
Morgane Magnin, Philippe Guillaume, George Coukos, Alexandre Harari and Julien Schmidt
3. In vitro assays for effector T cell functions and activity of immunomodulatory antibodies
Roberta Zappasodi, Sadna Budhu, Mohsen Abu-Akeel and Taha Merghoub
4. A cytofluorimetric assay to evaluate T cell polyfunctionality
Belinda Palermo, Mariangela Panetta, Giulia Campo and Paola Nisticò
5. Assessment of memory formation by metabolically engineered antigen-specific CD8 T cells
Mathias Wenes, Pedro Romero and Lianjun Zhang
6. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models
Mahmoud S. Alghamri, Felipe J. Núñez, Neha Kamran, Stephen Carney, David Altshuler, Pedro R. Lowenstein and Maria G. Castro
7. Methods to edit T cells for cancer immunotherapy
Francesca Lucibello, Silvia Menegatti and Laurie Menger
8. Generating stem-like memory T cells with antioxidants for adoptive cell transfer immunotherapy of cancer
Karolina Pilipow, Eloise Scamardella and Enrico Lugli
9. Reverse immunology: From peptide sequence to tumor-killing human T-cell clones
Christophe Vanhaver, Monica Gordon-Alonso, Alexandre Bayard, Maria Teresa Catanese, Didier Colau, Pierre van der Bruggen and Annika M. Bruger
10. Generation of TCR-engineered reference cell samples to control T-cell assay performance
Nicole Bidmon, Cécile Gouttefangeas and Sjoerd H. van der Burg
11. In vitro expansion of Vγ9Vδ2 T cells for immunotherapy
Christian Peters, Léonce Kouakanou, Hans-Heinrich Oberg, Daniela Wesch and Dieter Kabelitz
12. CFSE dilution to study human T and NK cell proliferation in vitro
Iñigo Terrén, Ane Orrantia, Joana Vitallé, Olatz Zenarruzabeitia and Francisco Borrego
13. Rapid isolation and enrichment of mouse NK cells for experimental purposes
Maite Alvarez, Maria C. Ochoa, Luna Minute, Ignacio Melero and Pedro Berraondo
14. Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood
Peter Holicek, Iva Truxova, Lenka Kasikova, Sarka Vosahlikova, Cyril Salek, Jana Rakova, Monika Holubova, Daniel Lysak, Isabelle Cremer, Radek Spisek and Jitka Fucikova
15. Two-dimensional dynamic evaluation of natural killer cell-mediated lysis of adherent target cells
Alexandra Frazao, Louise Rethacker and Anne Caignard
16. Rapid isolation of mouse ILCs from murine intestinal tissues
Kyle Burrows, Pailin Chiaranunt, Louis Ngai and Arthur Mortha
17. Detecting and analyzing murine innate lymphoid cells
Alejandra Gomez-Cadena, Pedro Romero, Sara Trabanelli and Camilla Jandus
18. A cytofluorimetric assay to evaluate intracellular cytokine production by NK cells
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Segundo González and Alejandro López-Soto
19. Applications of microfluidic devices in advancing NK-cell migration studies
Xiaoou Ren, Abdulaziz Alamri, Jolly Hipolito, Francis Lin and Sam K.P. Kung
20. Complementary approaches to study NKT cells in cancer
Jay A. Berzofsky, Purevdorj B. Olkhanud and Masaki Terabe
21. Assessment of IFN-γ and granzyme-B production by in "sitro" technology
Claudia Galassi, Gwenola Manic, Martina Musella, Antonella Sistigu and Ilio Vitale
22. Assessment of IFNγ responsiveness in patient-derived xenografts
Jordan J. Cardenas, Camila Robles-Oteiza and Katerina Politi
23. Real-time cell analysis (RTCA) to measure killer cell activity against adherent tumor cells in vitro
Hans-Heinrich Oberg, Christian Peters, Dieter Kabelitz and Daniela Wesch
24. Analysis of cancer cell-intrinsic immune regulation in response to CD8+ T cell attack
Natalie J. Neubert, Laure Tillé, Christophe Martignier, Silvia A. Fuertes Marraco and Daniel E. Speiser
25. A flow cytometry-based method to screen for modulators of tumor-specific T cell cytotoxicity
Javier Santos, Jesús Ogando, Rosa Ana Lacalle and Santos Mañes
26. Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay
Seila Lorenzo-Herrero, Christian Sordo-Bahamonde, Segundo González and Alejandro López-Soto
27. 51Cr-release to monitor NK cell cytotoxicity
Leslie Elsner and Ralf Dressel


Description

Tumor Immunology and Immunotherapy – Cellular Methods Part A, Volume 631, the latest release in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. New chapters include Detection of intracellular cytokine production by T cells with flow cytometry, High-throughput identification of human antigen-specific CD8+ and CD4+ T cells using soluble pMHC multimers, In vitro assays for effector T cell functions and activity of immunostimulatory antibodies, Ex vivo energetic profiling of tumor cells and T cells from mouse models and human samples, A cytofluorimetric assay to evaluate T cell polyfunctionality, and much more.

Key Features

  • Contains the authority of authors who are leaders in their field
  • Provides a comprehensive source on new methods and research in enzymology

Readership

Experts in the field who may want to expand their technical horizons and to newcomers who need detailed introductions to basic techniques


Details

No. of pages:
554
Language:
English
Copyright:
© Academic Press 2020
Published:
17th January 2020
Imprint:
Academic Press
Hardcover ISBN:
9780128186732
eBook ISBN:
9780128186749

Ratings and Reviews


About the Serial Volume Editors

Lorenzo Galluzzi

Lorenzo Galluzzi

Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology with the Department of Radiation Oncology of the Weill Cornell Medical College (New York, NY, USA), Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine (New Haven, CT, USA), Honorary Associate Professor with the Faculty of Medicine of the Paris Descartes University (Paris, France), and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara (Ferrara, Italy) and the Graduate School of Pharmacological Sciences of the University of Padova (Padova, Italy). Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team “Apoptosis, Cancer and Immunity” at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris Sud University (Le Kremlin-Bicetre, France; 2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), Co-chair of the Society for Immunotherapy of Cancer (SITC) Immunogenic Cell Death Working Group, and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP). Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 400 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he is currently the 6th and the youngest of the 30 most-cited European cell biologists (relative to the period 2007–2013), and he was nominated Highly Cited Researcher by Clarivate Analytics (formerly, Thomson Reuter) in 2016 and 2018. Lorenzo Galluzzi currently operates as Editor-in-Chief of three journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, Lorenzo Galluzzi currently serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease. Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology with the Department of Radiation Oncology of the Weill Cornell Medical College (New York, NY, USA), Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine (New Haven, CT, USA), Honorary Associate Professor with the Faculty of Medicine of the Paris Descartes University (Paris, France), and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara (Ferrara, Italy) and the Graduate School of Pharmacological Sciences of the University of Padova (Padova, Italy). Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team “Apoptosis, Cancer and Immunity” at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris Sud University (Le Kremlin-Bicetre, France; 2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), Co-chair of the Society for Immunotherapy of Cancer (SITC) Immunogenic Cell Death Working Group, and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP). Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 400 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he is currently the 6th and the youngest of the 30 most-cited European cell biologists (relative to the period 2007–2013), and he was nominated Highly Cited Researcher by Clarivate Analytics (formerly, Thomson Reuter) in 2016 and 2018. Lorenzo Galluzzi currently operates as Editor-in-Chief of three journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, Lorenzo Galluzzi currently serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease.

Affiliations and Expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Nils-Petter Rudqvist

Nils-Petter Rudqvist

Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoint blockade treatment. Nils-Petter has also defined unique patters of expansion of TCR clonotypes in patients who respond or not to treatment with radiotherapy and ipilimumab. He has published 20 articles in peer-reviewed scientific journals and 60+ scientific conference abstracts.

Affiliations and Expertise

Postdoctoral Associate in Radiation Oncology, Weill Cornell Medicine, USA